Research and Markets: Drug Patent Challenge Report 2010 Profiles More than 60 Companies to Date

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/355eb0/drug_patent_challe) has announced the addition of the "Drug Patent Challenge Report 2010" report to their offering.

The Drug Patent Challenge Report profiles the companies that successfully challenged pharmaceutical drugs patents.

Using data on drugs approved from 2000 to 2009, this report provides complete lists of:

  • A list of the companies with the most successful patent challenges
  • A list of all the drugs for which each firm successfully challenged a patent
  • A list of all the companies that have received FDA approval for each listed drug

Report Highlights:

  • More than 60 companies profiled
  • More than 80 drugs profiled

Key Topics Covered:

  • Patent Challenger List
  • Details by Patent Challenger
  • ACTAVIS TOTOWA
  • BAKER NORTON
  • BARR
  • BAUSCH AND LOMB
  • BAXTER HLTHCARE
  • BEDFORD
  • COBALT
  • DR REDDYS LABS LTD
  • ENDO PHARMS
  • GENEVA PHARMS
  • IMPAX LABS
  • KALI LABS
  • KV PHARM
  • LUPIN
  • MYLAN TECHNOLOGIES
  • NYCOMED US
  • OHM LABS
  • PAR PHARM
  • PERRIGO
  • SANDOZ
  • TARO
  • TEVA
  • THREE RIVERS PHARMS
  • TORPHARM
  • UPSHER SMITH
  • WATSON LABS FLORIDA
  • WYETH CONS
  • Details by Drug

For more information visit http://www.researchandmarkets.com/research/355eb0/drug_patent_challe



CONTACT:

Research and Markets
Laura Wood, Senior Manager
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.